Role of cell cycle events and apoptosis in mediating the anti-cancer activity of a silver(I) complex of 4-hydroxy-3-nitro-coumarin-bis(phenanthroline) in human malignant cancer cells

被引:60
作者
Thati, Bhumika [1 ]
Noble, Andy [1 ]
Creaven, Bernadette S. [1 ]
Walsh, Maureen [1 ]
McCann, Malachy [2 ]
Devereux, Michael [3 ]
Kavanaghe, Kevin [4 ]
Egan, Denise A. [1 ]
机构
[1] Dublin Inst Technol, Dept Sci, Dublin 24, Ireland
[2] Natl Univ Ireland, Dept Chem, Maynooth, Kildare, Ireland
[3] Dublin Inst Technol, Inorgan Pharmaceut & Biomimet Res Lab, Dublin 1, Ireland
[4] Natl Univ Ireland, Dept Biol, Maynooth, Kildare, Ireland
关键词
Apoptosis; Caspase activity; PARP cleavage; Cell cycle progression; Silver-coumarin-phenanthroline complex; ACTIVATED PROTEIN-KINASE; CENTER-DOT 2H(2)O; IN-VITRO; DNA-BINDING; COUMARIN DERIVATIVES; COLORIMETRIC ASSAY; CARCINOMA-CELLS; METAL-COMPLEXES; MELANOMA-CELLS; CYTO-TOXICITY;
D O I
10.1016/j.ejphar.2008.11.020
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The central objective of the current study was to investigate the potential in vitro anti-proliferative effect of 4-hydroxy-3-nitro-coumarin (hncH), and the mixed-ligand silver (I) complex of 4-oxy-3-nitro-coumarin-bis (phenanthroline), [Ag(hnc)(phen)(2)] using four human-derived model cell lines. In addition, selected mechanistic studies were carried out using the most sensitive of the four cell lines. Results obtained show that the complex could decrease the proliferation of all four cell lines including neoplastic renal and hepatic, namely A-498 and HepG(2) cells, respectively, along with two non-neoplastic renal and hepatic cell lines, HK-2 and Chang, respectively. Furthermore, non-neoplastic hepatic cells (Chang) appeared to be less sensitive to the effect of the complex, but this effect was not replicated in the non-neoplastic renal (HK-2) cells. Based on IC50 values [Ag(hnc)(phen)(2)] was shown to be almost four times more potent than cisplatin, using HePG(2) cells. In addition, the observed anti-proliferative effect was shown to be both dose- and time-dependent. Furthermore, the complex was shown to decrease DNA synthesis, but did not intercalate with it. Moreover, there was no evidence that P-glycoprotein-mediated multi-drug resistance was likely to decrease antiproliferative activity. Cytological stains, analysis of genomic DNA, and biochemical assays [caspase-3 and -9 and cleaved poly(ADP-ribose)-polymerase protein] showed that cell death appeared to result from apoptosis, with the possibility of secondary necrosis. Additionally, flow cytometric analysis showed that the complex functioned through an alteration in cell cycle progression. Taken together, [Ag(hnc)(phen)(2)] has been shown to be a more potent anti-proliferative agent than cisplatin, capable of altering key biochemical events leading to cell death. Additional mechanistic studies are underway to probe more fully its mechanism of action. (C) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:203 / 214
页数:12
相关论文
共 74 条
[41]  
2-S
[42]  
Kostova Irena P., 2004, Acta Pharmaceutica (Zagreb), V54, P37
[43]   What are caspases 3 and 7 doing upstream of the mitochondria? [J].
Kuribayashi, Kageaki ;
Mayes, Patrick A. ;
El-Deiry, Wafik S. .
CANCER BIOLOGY & THERAPY, 2006, 5 (07) :763-765
[44]   Synthesis and in vitro evaluation of novel highly potent coumarin inhibitors of gyrase B [J].
Laurin, P ;
Ferroud, D ;
Klich, M ;
Dupuis-Hamelin, C ;
Mauvais, P ;
Lassaigne, P ;
Bonnefoy, A ;
Musicki, B .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1999, 9 (14) :2079-2084
[45]   Synthesis, characterization and biological activity of lanthanum(III) complexes containing 2-methylene-1,10-phenanthroline units bridged by aliphatic diamines [J].
Li, FH ;
Zhao, GH ;
Wu, HX ;
Lin, H ;
Wu, XX ;
Zhu, SR ;
Lin, HK .
JOURNAL OF INORGANIC BIOCHEMISTRY, 2006, 100 (01) :36-43
[46]   Copper and genomic stability in mammals [J].
Linder, MC .
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2001, 475 (1-2) :141-152
[47]  
LORCOZIO A, 1993, EUR J CANCER, V29, P1985
[48]   Anticancer drugs of tomorrow: apoptotic pathways as targets for drug design [J].
Los, M ;
Burek, CJ ;
Stroh, C ;
Benedyk, K ;
Hug, H ;
Mackiewicz, A .
DRUG DISCOVERY TODAY, 2003, 8 (02) :67-77
[49]  
MACLEOD RA, 1952, J BIOL CHEM, V197, P751
[50]  
MARSHALL ME, 1986, AM SOC ONCOL, V5, P186